CLN-619 is under clinical development by Cullinan Therapeutics and currently in Phase I for Relapsed Multiple Myeloma.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...
The early detection of cancer in patients in Sussex has risen to its highest ever level, according to new NHS analysis. Of ...
Edgardo S. Santos, MD, FACP, FASCO, discussed the barriers to precision medicine in lung cancer treatment, including patient ...
Researchers have discovered why the lungs are often targeted by metastasizing cancer cells, pinpointing the amino acid ...
The family of a retired Westchester school employee is reaching out to the community for help as they raise funds for a ...
Beth Sandy, MSN, CRNP, FAPO, led a discussion on EGFR-mutated non-small cell lung cancer, focusing on targeted therapies for ...
By narrowing their research to overweight and obese individuals, Roswell Park researchers found that metformin might offer ...
On December 20, 2024, the FDA granted accelerated approval to the combination of encorafenib (Braftovi), cetuximab (Erbitux), ...
China National Medical Products Administration (NMPA) has granted acceptance and priority review for the new drug application ...
CURE compiled the top stories in the lung cancer space, including treatment updates and the potential of cancer vaccines.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback